Glaukos Corporation (NYSE: GKOS) is a Healthcare company (Medical - Devices) with a market capitalization of $14.4B. The Maz Rating grades it against the other companies in its sector.
Glaukos Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $243.25, Glaukos Corporation trades at 20.9x sales and 20.1x book value. Over the last twelve months it generated about $688M of revenue and a net loss of $173M. It runs a gross margin of 81.1%, an operating margin of -9.2% and a net margin of -24.6%. It shows return on equity of -24.9%, return on invested capital of -7.2% and a free cash flow yield of 0.3%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 4.57. Over the past 52 weeks the share price ranged from $73.16 to $255.19, with a beta of 0.69.
Glaukos Corporation does not currently pay a dividend.
25 Wall Street analyst ratings cover the stock: 18 Buy, 6 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.